Pharmacokinetics of angiotensin II type 1 receptor antagonists: Focus on losartan candesartan cilexetil and valsartan

Canadian Journal of Clinical Pharmacology

Volumn 5, Issue 1, 1998, Pages 14-22

  Turgeon, Jacques ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Angiotensin II type 1 receptor antagonist; Candesartan cilexetil; Losartan; Pharmacokinetics; Valsartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II ANTAGONIST; CANDESARTAN HEXETIL; DRUG METABOLITE; LOSARTAN; PRODRUG; VALSARTAN;

CONGESTIVE HEART FAILURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HYDROLYSIS; HYPERTENSION; REVIEW;

EID: 0031898533     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Erdos EG. Angiotensin I converting enzyme. Circ Res 1975;36:247-55.
2. Peach MJ. Renin-angiotensin system: Biochemistry and mechanisms of action. Physiol Rev 1977;57:313-70.
3. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153:937-42.
4. Vallotton MB. The renin-angiotensin system. Trends Pharmacol Sci 1987;8:69-74.
5. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988;77:I4-I13.
6. Ragugi H, Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994;90:449-55.
7. Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharmacol 1993;22(Suppl 5):S1-9.
8. Kurtz A, Scholz H, della Bruna R. Molecular mechanisms of renin release. J Cardiovasc Pharmacol 1990;16:S1-S7.
9. Helmer OM. Differentiation between two forms of angiotonin by means of spirally cat strips of rabbit aorta. Am J Physiol 1957;188:571-7.
10. Braun-Menéndez E, Fasciolo JC, Leloir LF, Munoz JM. The substance causing renal hypertension. J Physiol 1940:98:283-98.
11. Page IH, Helmer OM. Angiotonin-activator, renin- and angiotonin-inhibitor and the mechanism of angiotonin tachyphylaxis in normal, hypertensive and nephrectomized animals. J Exp Med 1940;71:485-519.
12. Ng KK, Vane JR. Conversion of angiotensin I to angiotensin II. Nature 1967;216:762-6
13. Kurtz TW. The ACE of hearts. Nature 1992;359:588-9.
14. Urata H, Hoffmann S, Ganten D. Tissue angiotensin II system in the human heart. Eur Heart J 1994;15(Suppl D):68-78.
15. Paul M, Wagner J, Dzau VJ. Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J Clin Invest 1993;91:2058-64.
16. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-57.
17. Urata H, Ganten D. Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase. Eur Heart J 1993;14:177-82.
18. Dzau VJ. Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J Hypertens 1989;7:933-6.
19. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
20. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995;96:2515-20.
21. Ferrario CM. Biological roles of angiotensin-(1-7). Hypertens Res 1992;15:61-6.
22. Sasaki K, Yamano Y, Bardhan S, et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991;351:230-3.
23. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991;351:233-6.
24. Mukoyama M, Kakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993;268:24539-42.
25. Nakajima M, Mukoyama M, Pratt RE, Horiuchi M, Dzau VJ. Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem Biophys Res Commun 1993;197:393-9.
26. Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotensin 11 receptor subtypes. Biochem Biophys Res Commun 1989;163:284-91.
27. Chiu AT, Herblin WF, McCall DE, et al. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989;165:196-203.
28. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995;346:1403-7.
29. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.
30. Reithmann C, Werdan K. Homologous vs heterologous desensitization of the adenylate cyclase system in heart cells. Eur J Pharmacol 1988;154:99-104.
31. Zola B, Kahn JK, Juni JE, Vinik AI. Abnormal cardiac function in diabetic patients with autonomic neuropathy in the absence of ischemic heart disease. J Clin Endocrinol Metab 1986;63:208-14.
32. Pals DT, Masucci FD, Denning GSJ, Sipos F, Fessier DC. Role of the pressor action of angiotensin 11 in experimental hypertension. Circ Res 1971;29:673-81.
33. Anderson GHJ, Streeten DHP, Dalakas TG. Pressor responses to 1-Sar-8-Ala-angiotensin II (saralasin) in hypertensive subjects. Circ Res 1977;40:243-50.
34. Case D, Wallace J, Keim H, Sealey J, Laragh J. Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II for evaluating the renin and sodium factors in hypertensive patients. Am J Med 1976;60:825-36.
35. Furakawa Y, Kishimoto S, Nishikawa K. Hypotensive Imidazole Derivatives and Hypotensive Imidazole-5-Acetic Acid Derivatives. Tokyo: Takeda Chemical Industries O, 1982.
36. Carini DJ, Duncia JV. The discovery and development of the nonpeptide angiotensin II receptor antagonists. Adv Med Chem 1993;2:153-95.
37. Duncia JV, Carini DJ, Chiu AT, et al. The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist. Med Res Rev 1992;12:149-91.
38. Timmermans PB, Duncia JV, Carini DJ, et al. Discovery of losartan, the first angiotensin II receptor antagonist. J Hum Hypertens 1995;9:S3-18.
39. Lane EA, Levy RH. Prediction of steady-state behavior of metabolite from dosing of parent drug. J Pharm Sci 1980;69:610-2.
40. Wong PC, Price WA Jr, Chiu AT, et al. Nonpeptide angiotensin n receptor antagonists. IV. EXP6155 and EXP6803. Hypertension 1989;13:489-97.
41. Wong PC, Price WA Jr, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonist: studies with EXP9270 and DuP 753. Hypertension 1990;15:823-34.
42. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-9.
43. Ohtawa NC, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35(6):290-7.
44. Spielberg S, McCrea J, Cribb A, et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther 1996;59:215. (Abst)
45. Losartan Potassium Prescribing Information. Pennysylvania: Merck & Co Inc, 1995.
46. Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 1995;23:285-9.
47. Stearns RA, Chakravarty PK, Chen R, Chiu SHL. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995;23:207-15.
48. Stearns RA, Miller RR, Doss GA, et al. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and liver slices. Drug Metab Disp 1992;20:281-7.
49. Wong PC, Price WA Jr, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255:211-7.
50. Bumpus FM, Khosla MC. Angiotensin analogs as determinants of the physiologic role of angiotensin and its metabolites. In: Genest J, Koew E, Kuchel O, eds. Hypertension. New York: McGraw-Hill, 1977:183-201.
51. Christ DD, Wong PC, Wong YN, Hart SD, Quon CY, Lam GN. The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. J Pharmacol Exp Ther 1994;268:1199-205.
52. Chan DP, Sandok EK, Aarhus LL, Heublein DM, Burnett JC Jr. Renal specific actions of angiotensin II receptor antagonism in the anesthetized dog. Am J Hypertens 1992;5:354-60.
53. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
54. Smith RD, Sweet CS, Goldberg A, Timmermans PB. Losartan potassium (COZAAR™) a nonpeptide antagonist of angiotensin II. Drugs of Today 1995;31:463-98.
55. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin 11 receptor antagonist. Clin Pharmacol Ther 1992;51:513-21.
56. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996;51:820-45.
57. Christ DD. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 1995;35:515-20.
58. Sica DA, Lo MW, Shaw WC, et al. The pharmacokinetics of losartan in renal insufficiency. J Hypertens 1995;13:S49-52.
59. Cohen JL. Pharmacokinetic changes in aging. Am J Med 1986;80(Suppl 5A):31-8.
60. Crooks J, O'Malley K, Stevenson IH. Pharmacokinetics in the elderly. Clin Pharmacokinet 1976;1:280-6.
61. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995;75:793-5.
62. 1-selective non-peptide angiotensin II receptor antagonist. Eur J Clin Pharmacol 1995;49:115-9.
63. Goldberg MR, Lo MW, Deutsch PJ, Wilson SE, McWilliams EJ, McCrea JB. Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther 1996;59:268-74.
64. De Smet M, Schoors DF, De Meyer G, et al. Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br J Clin Pharmacol 1995;40:571-5.
65. McCrea JB, Lo MW, Tomasko L, et al. Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. J Clin Pharmacol 1995;35:1200-6.
66. Kaminsky LS, De Morais SMF, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol Pharmacol 1993;43:234-9.
67. Kong ANT, Tomasko L, Waldman SA, et al. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995;35:1008-15.
68. Shibouta Y, Inada Y, Ojima M, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2́-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993;266:114-20.
69. Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. Disposition on the new angiotensin II receptor antagonist, candesartan cilexetil, in rats and dogs. Drug Res 1996;46:594-600.
70. Ogihara T, Nagano M, Mikami H, et al. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994;16:74-86.
71. Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid aromatography/electrospray tandem mass spectrometry following chemical derivatization. J Mass Spectrom 1996;31:873-8.
72. Delacréataz E, Nussberger J, Biollaz J, Waeber B, Brunner HR. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995;25:14-21.
73. Ogihara T, Arakawa K, Emura O, et al. Open clinical studies on a new angiotensin II receptor antagonist, TCV-116. J Hypertens 1994;12:S35-8.
74. 1-receptor subtype. Br J Pharmacol 1993;110:771.
75. Criscione L, Bradley WA, Buhlmayer P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Rev 1995;13:230-50.
76. Diovan™. Angiotensin II Antagonist for Antihypertensive Treatment. Summary of Product Characteristics. Basel: Ciba-Geigy Limited, 1996.
77. Mueller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994;47:231-45.
78. Mueller P, Flesch G, de Gasparo M, Turri M, Preiswerk G, Howald H. Single- and multiple-dose phase I trials with the angiotensin II antagonist valsartan. J Hypertens 1994;11:S459-60.
79. Perrier L, Bourrié M, Marti É, et al. In vitro N-glucuronidation of SR 47436 (BMS 186295), a new AT, nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharmacol Exp Ther 1994;271:91-9.